uniQure to Participate in Multiple Upcoming Industry Conferences
March 01 2019 - 7:00AM
uniQure to Participate in Multiple Upcoming Industry
Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in March:
- Leerink Global Health Care Conference in New York
City
- Matt Kapusta, chief executive
officer at uniQure, will participate in a fireside chat on Friday,
March 1 at 9:30 a.m. ET. The live webcast can be accessed through
the link displayed in the Investor section of the uniQure website.
The webcast replay will be available for at least 72 hours
following the live event.
- Cowen & Co. Healthcare Conference in Boston,
Mass.
- Matt Kapusta will present a
corporate update on Tuesday, March 12 at 10:40 a.m. ET. The live
webcast can be accessed through the link displayed in
the Investor section of the uniQure website. The webcast
replay will be available for at least 72 hours following the live
event.
- Barclays Healthcare Conference in Miami,
Florida
- Sander van Deventer, M.D., Ph.D.,
chief scientific officer at uniQure, will present a corporate
update and participate in a fireside chat on Wednesday, March 13 at
1:35 p.m. ET. The live webcast can be accessed through the link
displayed in the Investor section of the uniQure website. The
webcast replay will be available for at least 72 hours following
the live event.
- BioCapital Europe by LSP in Amsterdam, the
Netherlands
- Christian Klemt, chief accounting
officer at uniQure, will present a corporate update on Thursday,
March 14 at 2:30 p.m. CET.
- Gene Therapy for Rare Disorders Conference in Boston,
Mass.
- Daniel Leonard, senior director of
global patient advocacy at uniQure, will participate in the panel
discussion “Patient Advocacy in the Gene Therapy Space: A Case
Study in Hemophilia” on Wednesday, March 27 at 5:30 p.m. ET.
- Jonathan Garen, chief business
officer at uniQure, will present “The Emerging Business Models for
Commercializing Gene Therapy Treatment for Hemophilia” on Thursday,
March 28 at 11 a.m. ET.
Cold Spring Harbor Conference on
RNA and Oligonucleotide Therapeutics in Cold Spring Harbor, NY
- Melvin Evers, Ph.D., associate
director of emerging technologies at uniQure, will present
“Development of microRNA-based gene therapy for Huntington’s
disease” at the conference on Thursday, March 28.
- Marina Sogorb-Gonzalez, Ph.D.
student at uniQure, will also present “Transfer of therapeutic
miRNAs within extracellular vesicles secreted from Huntington’s
disease iPSC-derived neurons” at the conference, which takes place
March 27-30.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and other severe genetic diseases.
www.uniQure.com
uniQure Contacts |
|
|
|
|
|
For Investors: |
|
For Media: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024